CVS Health (CVS) saw two solid quarters of execution and early signs of progress in fixing its healthcare benefits business, UBS Securities said in a note Monday.
The company last month reported Q2 non-GAAP earnings and revenue above analyst expectations and raised its 2025 adjusted EPS guidance.
The brokerage said it now models earnings per share compound annual growth of 14% through 2028, above the 12% consensus forecast. The benefit cuts and assumptions CVS made around Medicare Advantage utilization this year "have proved to be on-point."
The firm also projects CVS will return to a mid-3 times leverage ratio by Q4 2026, providing room for buybacks to further support earnings growth.
UBS upgraded CVS to buy from neutral and raised the company's price target to $79 from $67.
Shares of CVS Health were up 2.5% in recent trading.
Price: 70.32, Change: +1.72, Percent Change: +2.51
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。